Outset Medical’s stock jumped 22.2% in the most recent trading session, marking its largest one-day gain in over eight months. Trading volume reached approximately 2.3 million shares, more than double the three-month daily average of 1.1 million, as institutional investors and hedge funds increased their holdings. Despite the sharp rally, analysts’ consensus revenue forecasts for fiscal 2024 have drifted lower by an average of 3.4% over the past four weeks, suggesting expectations of near-term demand headwinds in certain regional markets. Open interest in January and February call options also rose by 45%, indicating heightened bullish sentiment among derivatives traders.

At the 44th Annual J.P. Morgan Healthcare Conference held on January 13, Outset Medical’s management team highlighted robust growth metrics for its Tablo® Hemodialysis System. The company reported that its installed base expanded to 520 units across 18 countries as of year-end 2023, up from 340 units a year earlier, driving revenue of $35.8 million in Q4—a 58% year-over-year increase. CEO Scott Daly reiterated full-year guidance of $150 million to $155 million in equipment and consumables revenue, and noted a reduction in manufacturing costs that improved gross margin by 210 basis points to 59.4% in Q4. CFO Greg Flesher announced that operating cash flow turned positive at $2.1 million for the quarter, compared with an outflow of $4.7 million in Q4 2022.